Journal Home > Volume 8 , Issue 4

Mesenchymal stromal cells (MSCs) including mesenchymal stem cells to potentially differentiate into different tissue lineages widely exist in various tissues. In recent years, the clinical research and application of MSCs have become more extensive, but no standardized guidelines for the preparation and quality control of clinical-grade MSCs currently exist. To standardize the preparation and quality control of MSCs using the human umbilical cord, placenta, bone marrow, and adipose tissue as sample sources for the Chinese Association of Neurorestoratology (CANR; Preparatory) and the China Committee of International Association of Neurorestoratology (IANR-China Committee) member units, this standard is formulated following the T11/CSSCR 001-2017 General Requirements for Stem Cells, Good Manufacturing Practice Pharmaceutical Products (2010 Edition), Pharmacopoeia of the People's Republic of China (2015 Edition), Guiding Principles for Quality Control of Stem Cell Preparations and Preclinical Research (Trial), Code for Cell Banking Facility Quality Management, Sterile Drug Appendix to Pharmaceutical Production Quality Management Regulations, GMP Appendix — Cell Therapy Products (Draft for Comment), The International Society for Cellular Therapy position statement (2006), and Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017). Moreover, this standard includes donor evaluation, sample collection, cell preparation, cell inspection, packaging, labeling, transportation and storage, and quality control. It represents the minimum requirements for clinical-grade mesenchymal stromal cell culture and quality control. Moreover, it will be further optimized following the progress of preclinical and clinical research.


menu
Abstract
Full text
Outline
About this article

Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version)

Show Author's information Shuanglin Xiang1,( )Wenyong Gao2Haining Peng3Aibing Liu4Qiang Ao5Manjun Yang3Yanqiu Yu6Ying Liu4Raoxing Rong7Raoxing Rong7
Landfar Bio-medicine Co., Ltd., Changsha 410015, Hunan, China
Beijing Hongtianji Neuroscience Academy, Beijing 100144, China
Hunan Landfar Amspring Biotechnology Co., Ltd., Changsha 410205, Hunan, China
Third Medical Center of General Hospital of PLA, Beijing 100039, China
Institute of Regulatory Science for Medical Device, National Engineering Research Center for Biomaterials, Sichuan University, Chengdu, Sichuan 610064, China
College of Basic Medical Sciences, China Medical University, Shenyang 110122, Liaoning, China
Shenyang Engineering Technology R&D Center of Cell Therapy Co., Ltd., Shenyang 110169, Liaoning, China

Abstract

Mesenchymal stromal cells (MSCs) including mesenchymal stem cells to potentially differentiate into different tissue lineages widely exist in various tissues. In recent years, the clinical research and application of MSCs have become more extensive, but no standardized guidelines for the preparation and quality control of clinical-grade MSCs currently exist. To standardize the preparation and quality control of MSCs using the human umbilical cord, placenta, bone marrow, and adipose tissue as sample sources for the Chinese Association of Neurorestoratology (CANR; Preparatory) and the China Committee of International Association of Neurorestoratology (IANR-China Committee) member units, this standard is formulated following the T11/CSSCR 001-2017 General Requirements for Stem Cells, Good Manufacturing Practice Pharmaceutical Products (2010 Edition), Pharmacopoeia of the People's Republic of China (2015 Edition), Guiding Principles for Quality Control of Stem Cell Preparations and Preclinical Research (Trial), Code for Cell Banking Facility Quality Management, Sterile Drug Appendix to Pharmaceutical Production Quality Management Regulations, GMP Appendix — Cell Therapy Products (Draft for Comment), The International Society for Cellular Therapy position statement (2006), and Clinical Cell Therapy Guidelines for Neurorestoration (IANR/CANR 2017). Moreover, this standard includes donor evaluation, sample collection, cell preparation, cell inspection, packaging, labeling, transportation and storage, and quality control. It represents the minimum requirements for clinical-grade mesenchymal stromal cell culture and quality control. Moreover, it will be further optimized following the progress of preclinical and clinical research.

Keywords: preparation, clinical-grade, mesenchymal stromal cell, quality control standard

References(13)

[1]
M Dominici, K Le Blanc, I Mueller, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006, 8(4): 315-317.
[2]
National Health and Family Planning Commission, China Food and Drug Administration. Guiding Principles for Quality Control of Stem Cell Preparations and Preclinical Research (Trial). 2015.
[3]
Chinese Society for Stem Cell Research. T11/CSSCR 001-2017 General Requirements for Stem Cells. Beijing: Standards Press of China, 2017.
[4]
China Medicinal Biotechnology Association. Code for Cell Banking Facility Quality Management. 2017.
[5]
Jiangsu Administration for Market Regulation. DB32/T3544-2019 Quality Control Technical Specifications Clinical Grade Mesenchymal Stem Cells from Human Tissues. 2019.
[6]
KE Jones, N Patel, M Levy, et al. Global trends in emerging infectious diseases. Nature. 2008, 451: 990-994.
[7]
Ministry of Health of the People's Republic of China. Good Manufacturing Practice for Pharmaceutical Products. 2010.
[8]
National Medical Products Administration. GMP Appendix — Cell Therapy Products (Draft for Comment). 2019.
[9]
A Qiang, X Juan, Y Yanqiu, et al. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application. J Neurorestoratology. 2018, 6: 11-15.
[10]
State Food and Drug Administration. Sterile Drug Appendix to Pharmaceutical Production Quality Management Regulations. 2011.
[11]
HY Huang, W Young, L Chen, et al. Clinical cell therapy guidelines for neurorestoration (IANR/CANR 2017). Cell Transplant. 2018, 27(2): 310-324.
[12]
Shenzhen Society for Cell Therapy Technology. SZTT/SSCT 002-2018 Product Specification of Human Umbilical Cord Derived Mesenchymal Stem Cell for Clinical Research. 2018.
[13]
Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. Beijing: China Medical Science and Technology Press, 2015.
Publication history
Copyright
Rights and permissions

Publication history

Received: 23 September 2020
Revised: 30 October 2020
Accepted: 04 November 2020
Published: 07 February 2021
Issue date: December 2020

Copyright

© The authors 2020

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com

Return